Estimating survival gain for economic evaluations with survival time as principal endpoint: A cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer

2002 ◽  
Vol 11 (3) ◽  
pp. 233-248 ◽  
Author(s):  
N. Neymark ◽  
I. Adriaenssen ◽  
T. Gorlia ◽  
S. Caleo ◽  
M. Bolla
Keyword(s):  
Prostate Cancer ◽  
Cost Effectiveness ◽  
Survival Time ◽  
Hormonal Therapy ◽  
Advanced Prostate Cancer ◽  
Locally Advanced ◽  
Cost Effectiveness Analysis ◽  
Economic Evaluations ◽  
Locally Advanced Prostate Cancer ◽  
Effectiveness Analysis

Cost–effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer

2013 ◽  
Vol 13 (2) ◽  
pp. 261-270 ◽  
Author(s):  
Hind T Hatoum ◽  
E David Crawford ◽  
Sandy Kildegaard Nielsen ◽  
Swu-Jane Lin ◽  
Dennis C Marshall
Keyword(s):  
Prostate Cancer ◽  
Cost Effectiveness ◽  
Hormonal Therapy ◽  
Advanced Prostate Cancer ◽  
Locally Advanced ◽  
Cost Effectiveness Analysis ◽  
Locally Advanced Prostate Cancer ◽  
Effectiveness Analysis

Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer

2001 ◽  
Vol 37 (14) ◽  
pp. 1768-1774 ◽  
Author(s):  
N Neymark ◽  
I Adriaenssen ◽  
T Gorlia ◽  
S Caleo ◽  
M Bolla ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cost Effectiveness ◽  
Hormonal Therapy ◽  
Advanced Prostate Cancer ◽  
Locally Advanced ◽  
Locally Advanced Prostate Cancer

Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer

2013 ◽  
Vol 13 (2) ◽  
pp. 251-259 ◽  
Author(s):  
Hind T Hatoum ◽  
E David Crawford ◽  
Sandy Kildegaard Nielsen ◽  
Swu-Jane Lin ◽  
Dennis C Marshall
Keyword(s):  
Prostate Cancer ◽  
Hormonal Therapy ◽  
Advanced Prostate Cancer ◽  
Locally Advanced ◽  
Economic Evaluations ◽  
Locally Advanced Prostate Cancer

PREOPERATIVE CHEMOTHERAPY (CHT) AND HORMONAL THERAPY (AA) FOLLOWED BY RADICAL PROSTATECTOMY (RP) FOR LOCALLY ADVANCED PROSTATE CANCER (PCA)

1999 ◽  
pp. 300
Author(s):  
Curtis A. Pettaway ◽  
Louis L. Pisters ◽  
Patricia Troncoso ◽  
Laury D. Finn ◽  
Joel W. Slaton ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Preoperative Chemotherapy ◽  
Hormonal Therapy ◽  
Advanced Prostate Cancer ◽  
Locally Advanced ◽  
Locally Advanced Prostate Cancer

scholarly journals Impact of the Duration of Adjuvant Hormonal Therapy in Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy: A Secondary Analysis of RTOG 85-31

2009 ◽  
Vol 27 (13) ◽  
pp. 2137-2143 ◽  
Author(s):  
Luis Souhami ◽  
Kyounghwa Bae ◽  
Miljenko Pilepich ◽  
Howard Sandler
Keyword(s):  
Prostate Cancer ◽  
Regression Model ◽  
Randomized Trial ◽  
Hormonal Therapy ◽  
Advanced Prostate Cancer ◽  
Locally Advanced ◽  
Radiation Therapy Oncology Group ◽  
Disease Free Survival ◽  
Adjuvant Hormonal Therapy ◽  
Locally Advanced Prostate Cancer

PurposeRadiation Therapy Oncology Group 85-31 was a randomized trial of androgen suppression for life for patients with locally advanced prostate cancer. However, not all patients continued on the protocol-mandated long-term hormonal therapy despite no evidence of recurrence. We correlated duration of adjuvant hormonal therapy and outcomes among patients who prematurely discontinued hormonal therapy.Patients and MethodsThe protocol mandated pelvic radiotherapy followed by goserelin given indefinitely or until disease progression. There were 189 analyzable patients. Patients were divided in groups based on the tertile of hormonal therapy duration (HTD) as follows: ≤ 1 year, more than 1 year and ≤ 5 years, and more than 5 years. Overall survival (OS), disease-free survival (DFS), cause-specific mortality, local failure (LF), and distant metastasis (DM) were studied. Kaplan-Meier estimation and Cox proportional hazards regression model were used for OS and DFS, and Fine and Gray's regression model was used for the other outcomes.ResultsThe median follow-up for surviving patients is 9.6 years. The median duration of adjuvant hormonal therapy was 2.2 years. The HTD more than 5 years group is significantly associated with an improved survival and DFS and fewer DMs than other HTD groups. After adjustment for age, radical prostatectomy, nodal status, Gleason score, and stage variables, the HTD more than 5 years group remains significantly associated with better OS and DFS than other HTD groups.ConclusionIn this hypothesis-generating analysis, prolonged HTD of more than 5 years seems significantly associated with improvements in most outcomes. Given these data, decreasing HTD to ≤ 5 years may have a detrimental effect on patients with locally advanced prostate cancer. Only a randomized trial will conclusively clarify this issue.

Sign in / Sign up

Export Citation Format

Share Document